Eli Lilly Oncology Drug Olomorasib Receives FDA Orphan Drug Designation
Eli Lilly's experimental cancer treatment, olomorasib, has received orphan drug designation from the Food and Drug Administration, marking a regulatory win for the company's oncology pipeline.